Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

NCT05130970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Garadacimab
DRUG: Placebo

Sponsor

CSL Behring